The DOI matches its Crossref record.
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models
Open accessAbstract
The ability of cancer cells to undergo invasion and migration is a prerequisite for tumor metastasis. Rho, a Ras-related small GTPase, and the Rho-associated coiled coil–containing protein kinases (Rho kinases, ROCK1 and ROCK2) are key regulators of focal adhesion, actomyosin contraction, and thus cell motility. Inhibitors of this pathway have been shown to inhibit tumor cell motility and metastasis. Here, we show that fasudil [1-(5-isoquinolinesulfonyl)-homopiperazine], an orally available inhibitor of Rho kinases, and its metabolite 1-(hydroxy-5-isoquinoline sulfonyl-homopiperazine) (fasudil-OH) modify tumor cell morphology and inhibit tumor cell migration and anchorage-independent growth. In addition, we show that fasudil inhibited tumor progression in three independent animal models. In the MM1 peritoneal dissemination model, tumor burden and ascites production were reduced by >50% (P < 0.05). In the HT1080 experimental lung metastasis model, fasudil decreased lung nodules by ∼40% (P < 0.05). In the orthotopic breast cancer model with MDA-MB-231, there were 3-fold more tumor-free mice in the fasudil-treated group versus saline control group (P < 0.01). Fasudil has been approved for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms. In patients, fasudil is well tolerated without any serious adverse reactions. Therefore, the concept of Rho kinase inhibition as an antimetastatic therapy for cancer can now be clinically explored. [Mol Cancer Ther 2006;5(9):2158–64]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanics, malignancy, and metastasis: The force journey of a tumor cell
Kumar, S., & Weaver, V. M. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9173-4 · Cited by 928
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
Gandalovičová, A., Rosel, D., Fernandes, M., Veselý, P., Heneberg, P., Čermák, V., Petruželka, L., Kumar, S., Sanz-Moreno, V., & Brábek, J. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.008 · Cited by 351
Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor
Chapman, S., Liu, X., Meyers, C., Schlegel, R., & McBride, A. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42297 · Cited by 315
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
Rho-kinase as a target for cancer therapy and its immunotherapeutic potential
Kim, S., Kim, S. A., Han, J., & Kim, I.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312916 · Cited by 88
Metadata
- Authors
- Ying, H., Biroc, S. L., Li, W.-W., Alicke, B., Xuan, J.-A., Pagila, R., Ohashi, Y., Okada, T., Kamata, Y., & Dinter, H.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-09-01
- Volume
- 5
- Issue
- 9
- Pages
- 2158-2164
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2111807830
- Cited by
- 182
- References
- 0
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0440
- The paper
- Ying, H., Biroc, S. L., Li, W.-W., Alicke, B., Xuan, J.-A., Pagila, R., Ohashi, Y., Okada, T., Kamata, Y., & Dinter, H. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.